Free tool
FAERS Monitor: Gonal-F
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 020378 or its brand name (Gonal-F, Follitropin Alfa/Beta). Reports on generic versions are filed under their own applications.
Reports
2,046
Serious
1,696
83% of reports
Hospitalization
983
Death reported
32
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome696
- ascites223
- abdominal pain130
- abortion spontaneous123
- abdominal distension120
- nausea104
- dyspnoea100
- vomiting85
- inappropriate schedule of drug administration80
- drug ineffective78
- pleural effusion76
- off label use75
- drug exposure during pregnancy58
- maternal exposure during pregnancy54
- headache53
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 15 |
| 2005 | 21 |
| 2006 | 18 |
| 2007 | 45 |
| 2008 | 43 |
| 2009 | 44 |
| 2010 | 54 |
| 2011 | 65 |
| 2012 | 79 |
| 2013 | 109 |
| 2014 | 139 |
| 2015 | 114 |
| 2016 | 102 |
| 2017 | 174 |
| 2018 | 110 |
| 2019 | 165 |
| 2020 | 116 |
| 2021 | 45 |
| 2022 | 127 |
| 2023 | 143 |
| 2024 | 129 |
| 2025 | 100 |
| 2026 | 89 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,113 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 696 | 4374.7 | 4049.0 | 2,132,647 |
| ascitesSignal | 223 | 78.6 | 69.4 | 16,894 |
| abortion spontaneousSignal | 123 | 31.7 | 26.7 | 3,616 |
| drug exposure during pregnancySignal | 58 | 17.6 | 13.6 | 889 |
| pleural effusionSignal | 76 | 12.9 | 10.3 | 820 |
| abdominal distensionSignal | 120 | 11.8 | 9.9 | 1,183 |
| inappropriate schedule of drug administrationSignal | 80 | 11.6 | 9.3 | 764 |
| maternal exposure during pregnancySignal | 54 | 6.2 | 4.8 | 233 |
| abdominal painSignal | 130 | 5.7 | 4.9 | 510 |
| vomiting | 85 | 1.9 | 1.5 | 34 |
| dyspnoea | 100 | 1.8 | 1.5 | 37 |
| nausea | 104 | 1.4 | 1.1 | 9 |
| off label use | 75 | 0.9 | 0.7 | 1 |
| headache | 53 | 0.9 | 0.7 | 1 |
| drug ineffective | 78 | 0.6 | 0.5 | 21 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.